Prior to joining Ermium Therapeutics, Stéphane served as Chief Financial Officer & Head of Alliances and Business Development at Lysogene, a phase 3 clinical stage gene therapy company listed on Euronext, where he successfully led capital raising activities and closed the acquisition of two assets.
Previously, Stéphane spent nine years at Ipsen, first as Vice-President Head of Investor Relations for the group, then as CFO of Ipsen Iberia, in charge of financial, procurement and supply chain activities.
Earlier in his career, Stéphane worked in private equity at LaSalle Investment management, at Calyon Americas and at Exane BNP Paribas as a sell-side research analyst.
He holds a master’s degree (MSc) in accounting and finance from the London School of Economics (LSE) and in management from Paris Dauphine University. He also holds an executive leadership degree from Harvard Business School.
Management team
Scientific Advisor
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Board Of Directors
Scientific Advisory Board
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
